Form 4: Director Matthew Mazdyasni Receives Astrana Health Equity

Director Matthew Mazdyasni was granted 4,525 restricted shares of Astrana Health, Inc. common stock.

Summary

• Director Matthew Mazdyasni acquired 4,525 shares of common stock in Astrana Health, Inc. (ASTH).
• The shares were granted as restricted stock under the company's 2024 Equity Incentive Plan.
• The total beneficial ownership for the director following this transaction is 39,288 shares.
• The shares are subject to a vesting schedule tied to the earlier of June 10, 2027, or the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified in this filing.

Risks

• None identified in this filing.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term performance and align leadership with shareholder value in the healthcare services sector.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is consistent with standard practices among mid-cap healthcare companies.
• Vesting periods of one year for director equity are common in the industry to ensure retention and commitment.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation practices.

Next Steps

• Vesting of the 4,525 restricted shares on June 10, 2027, or the date of the 2027 annual meeting.

Key Dates

Keywords

Astrana Health, ASTH, Form 4, Insider Transaction, Equity Incentive Plan, Director Compensation